

FierceBiotech Names VaxInnate as One of the "Fierce 15" Biotech Companies of 2009

VaxInnate is "Fierce," on Leading Edge of Biotech

CRANBURY, NJ, June 29, 2009

VaxInnate Corporation, a biotechnology company that is pioneering breakthrough vaccine technology, announced today that it has been named to the annual FierceBiotech "Fierce 15" list, designating it as one of the top biotech companies of 2009.

The editors of FierceBiotech evaluated hundreds of privately-held firms based on criteria such as vision, revenue potential, quality of deals, strength of technology, partnerships, and competitive market position. VaxInnate was determined to be one of the "fiercest," based upon the firm's creativity and scientific innovation.

An internationally recognized daily newsletter reaching more than 65,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick authoritative briefing on the day's top stories, with a special focus on drug discovery and clinical trials.

"Biotechnology often attracts scientists who like to think big, and few developers are thinking as big as VaxInnate. The company is out to prove that it can create huge quantities of a highly effective influenza vaccine at a fraction of the current cost. And if they're right, they can reshape the entire industry while protecting the world from future pandemics," said John Carroll, Editor of FierceBiotech.

VaxInnate is pioneering breakthrough technology that could dramatically improve the potency, manufacturing capacity and cost-effectiveness of vaccines. The technology is based upon a proprietary combination of Toll-Like Receptor-mediated (TLR) immune enhancement and recombinant bacterial production of vaccine antigen.

The company's first vaccines focus on infectious diseases, including seasonal and pandemic flu, malaria, dengue, human papillomavirus (HPV) and respiratory syncytial virus (RSV). In 2008 and 2009, VaxInnate generated positive Phase I clinical data for its first two vaccines, a universal flu vaccine and a seasonal flu vaccine.

VaxInnate recently reported positive preclinical results for a recombinant swine flu vaccine it developed in less than three weeks, making it one of the first companies in the world to begin testing a vaccine that could help halt the spread of the swine flu pandemic. The company is hoping to partner with the U.S. Government on development of the swine flu vaccine and is seeking international partners for the development of this and other pandemic vaccines to meet global needs.

"FierceBiotech is respected for its thorough understanding of biotechnology companies and the industry as a whole," said Alan Shaw, PhD, President and CEO of VaxInnate. "Being selected as a member of the 'Fierce 15' is an honor that highlights VaxInnate's potential to make a significant impact in the biotech market and public health."

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. The complete list of 'Fierce 15' companies is available in today's issue of FierceBiotech and on the FierceBiotech Web site at www.fiercebiotech.com.

About FierceMarkets

FierceMarkets is a digital business media serving vertical markets with email newsletters, web sites, and live events. Based in Washington, D.C., FierceMarkets publications reach more than 450,000 executives in more than 100 countries every business day. Current publications include The Business VoIP Report (<http://www.businessvoipreport.com>), FierceBioResearcher

(<http://www.fiercebioresercher.com>), FierceBiotech (<http://www.fiercebiotech.com>), FierceBroadbandWireless (<http://www.fiercebroadbandwireless.com>), FierceCIO (<http://www.fiercecio.com>), Fierce CIO: Tech Watch (<http://www.fiercecio.com/techwatch>), FierceDeveloper (<http://www.fiercedevloper.com>), FierceFinance (<http://www.fiercefinance.com>), FierceFinanceIT (<http://www.fiercefinanceit.com>), FierceHealthCare (<http://www.fiercehealthcare.com>), FierceHealthFinance (<http://www.fiercehealthfinance.com>), FierceHealthIT (<http://www.fiercehealthit.com>), FierceIPTV (<http://www.fierceiptv.com>), FierceMobileContent (<http://www.fiercemobilecontent.com>), FierceMobileIT (<http://www.fiercemobileit.com>), FierceOnlineVideo (<http://www.fierceonlinevideo.com>), FiercePharma (<http://www.fiercepharma.com>), FierceSarbox (<http://www.fiercesarbox.com>), FierceTelecom (<http://www.fiercetelecom.com>), FierceVaccines (<http://www.fiercevaccines.com>), FierceVoIP (<http://www.fiercevoip.com>), FierceWireless (<http://www.fiercewireless.com>), and FierceWireless: Europe (<http://www.fiercewireless.com/europe>). |

About VaxInnate

VaxInnate is a privately-held biotechnology company in Cranbury, NJ that is pioneering **breakthrough technology** for use in developing novel and proprietary vaccines. VaxInnate's technology has the potential to dramatically improve the potency, manufacturing capacity and cost-effectiveness of vaccines.

VaxInnate's first vaccines focus on **infectious diseases**, including seasonal and pandemic flu, malaria, dengue, human papillomavirus and respiratory syncytial virus. In 2008 and 2009, VaxInnate generated positive Phase I clinical data for its first two vaccines, a universal flu vaccine and a seasonal flu vaccine. For more information about VaxInnate, please visit <http://www.vaxinnate.com>.

###

Contact:

Janet Skidmore

Office: 215-658-4915

Mobile: 215-429-2917

skidmorecomm@earthlink.net